<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2019-3-16-25</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group></article-categories><title-group><article-title>Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Клинические рекомендации по применению препарата окрелизумаб у пациентов с рассеянным склерозом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра неврологии, нейрохирургии и медицинской генетики, 117997, Москва, ул. Островитянова, 1;</p><p>отдел нейроиммунологии, 117997, Москва, ул. Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics, 1, Ostrovityanov St., Moscow 117997;</p><p>Department of Neuroimmunology, 10, Ostrovityanov St., Moscow 117997</p></bio><email xlink:type="simple">boykoan13@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдовская</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydovskaya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики,</p><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics, </p><p>1, Ostrovityanov St., Moscow 117997</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хачанова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khachanova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра неврологии, нейрохирургии и медицинской генетики,</p><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics,</p><p>1, Ostrovityanov St., Moscow 117997</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Захарова</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakharova</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>125367, Москва, Волоколамское шоссе, 80</p></bio><bio xml:lang="en"><p>80, Volokolamskoe Shosse, Moscow 125367</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Спирин</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Spirin</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра нервных болезней с медицинской генетикой и нейрохирургией,</p><p>150000, Ярославль, ул. Революционная, 5</p></bio><bio xml:lang="en"><p>Department of Nervous System Diseases with Medical Genetics and Neurosurgery, </p><p>5, Revolyutionnaya St., Yaroslavl 150000</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>127015, Москва, Писцовая ул., 10</p></bio><bio xml:lang="en"><p>10, Pistsovaya St., Moscow 127015</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алифирова</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Alifirova</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра неврологии и нейрохирургии,</p><p>634050, Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>Department of Neurology and Neurosurgery, </p><p>2, Moskovsky Road, Tomsk 634050</p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власов</surname><given-names>Я. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasov</surname><given-names>Ya. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра неврологии и нейрохирургии,</p><p>443099, Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Department of Neurology and Neurosurgery, </p><p>89, Chapaevskaya St., Samara 443099</p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сиверцева</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sivertseva</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>625000, Тюмень, ул. Шиллера, 12</p></bio><bio xml:lang="en"><p>12, Schiller St., Tyumen 625000</p></bio><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хабиров</surname><given-names>Ф. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khabirov</surname><given-names>F. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>420021, Казань, ул. Ватутина, 13</p></bio><bio xml:lang="en"><p>13, Vatutin St., Kazan 420021</p></bio><xref ref-type="aff" rid="aff-9"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шумилина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shumilina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197110, Санкт-Петербург, пр. Динамо, 11</p></bio><bio xml:lang="en"><p>11, Dynamo Pr., Saint Petersburg 197110</p></bio><xref ref-type="aff" rid="aff-10"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евдошенко</surname><given-names>Е. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Evdoshenko</surname><given-names>E. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197110, Санкт-Петербург, пр. Динамо, 11</p></bio><bio xml:lang="en"><p>11, Dynamo Pr., Saint Petersburg 197110</p></bio><xref ref-type="aff" rid="aff-10"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России;&#13;
ФГБУ «Федеральный центр цереброваскулярной патологии и инсульта» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia&#13;
Federal Center for Cerebrovascular Disease and Stroke, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр неврологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Center of Neurology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО Ярославский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yaroslavl State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ГБУЗ г. Москвы «Городская клиническая больница №24 Департамента здравоохранения г. Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital Twenty-Four, Moscow Healthcare Department</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-8"><aff xml:lang="ru"><institution>ОАО «Медико-санитарная часть «Нефтяник»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>OAO «Neftyannik» (Oilman) Primary Healthcare Unit</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-9"><aff xml:lang="ru"><institution>Республиканский клинико-диагностический центр по демиелинизирующим заболеваниям Минздрава Республики Татарстан</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Republican Clinical and Diagnostic Center for Demyelinating Diseases, Ministry of Health of the Republic of Tatarstan</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-10"><aff xml:lang="ru"><institution>Городской центр по лечению рассеянного склероза, Санкт-Петербургское ГБУЗ «Городская клиническая больница» №31</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital Thirty-One, City Center for Multiple Sclerosis Treatment</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>29</day><month>10</month><year>2019</year></pub-date><volume>11</volume><issue>3</issue><fpage>16</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Boyko A.N., Davydovskaya M.V., Khachanova N.V., Zakharova M.N., Spirin N.N., Popova E.V., Alifirova V.M., Vlasov Y.V., Sivertseva S.A., Khabirov F.A., Shumilina M.V., Evdoshenko E.P., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Бойко А.Н., Давыдовская М.В., Хачанова Н.В., Захарова М.Н., Спирин Н.Н., Попова Е.В., Алифирова В.М., Власов Я.В., Сиверцева С.А., Хабиров Ф.А., Шумилина М.В., Евдошенко Е.П.</copyright-holder><copyright-holder xml:lang="en">Boyko A.N., Davydovskaya M.V., Khachanova N.V., Zakharova M.N., Spirin N.N., Popova E.V., Alifirova V.M., Vlasov Y.V., Sivertseva S.A., Khabirov F.A., Shumilina M.V., Evdoshenko E.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1168">https://nnp.ima-press.net/nnp/article/view/1168</self-uri><abstract><p>The paper presents a detailed algorithm for the treatment and follow-up of patients with recurrent multiple sclerosis and primary progressive multiple sclerosis in the use of ocrelizumab.</p></abstract><trans-abstract xml:lang="ru"><p>В статье представлен подробный алгоритм лечения и наблюдения пациентов с рецидивирующими формами рассеянного склероза и первично-прогрессирующим рассеянным склерозом на фоне применения препарата окрелизумаб.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>окрелизумаб</kwd><kwd>рассеянный склероз</kwd><kwd>рецидивирующие формы рассеянного склероза</kwd><kwd>первично-прогрессирующий рассеянный склероз</kwd><kwd>моноклональное антитело</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ocrelizumab</kwd><kwd>multiple sclerosis</kwd><kwd>recurrent multiple sclerosis</kwd><kwd>primary progressive multiple sclerosis</kwd><kwd>monoclonal antibody</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Публикация статьи поддержана АО «РОШ-Москва».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Спирин НН, Бойко АН, Степанов ИО, Шмидт ТЕ, редакторы. Ведение больных с рассеянным склерозом. Методические рекомендации. Москва: Здоровье человека; 2015. 68 с.</mixed-citation><mixed-citation xml:lang="en">Spirin NN, Boiko AN, Stepanov IO, Shmidt TE, redaktory. Vedenie bol'nykh s rasseyannym sklerozom. Metodicheskie rekomendatsii [Management of patients with multiple sclerosis. Methodical recommendations]. Moscow: Zdorov'e cheloveka; 2015. 68 p.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lehmann PV, Rottlaender A, Kuerten S. The autoimmune pathogenesis of multiple sclerosis. Pharmazie. 2015 Jan;70(1):5-11.</mixed-citation><mixed-citation xml:lang="en">Lehmann PV, Rottlaender A, Kuerten S. The autoimmune pathogenesis of multiple sclerosis. Pharmazie. 2015 Jan;70(1):5-11.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Von Bü dingen HC, Palanichamy A, Lehmann-Horn K, et al. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015;73(3-4):238-46. doi: 10.1159/000377675. Epub 2015 Mar 25.</mixed-citation><mixed-citation xml:lang="en">Von Bü dingen HC, Palanichamy A, Lehmann-Horn K, et al. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015;73(3-4):238-46. doi: 10.1159/000377675. Epub 2015 Mar 25.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Claes N, Fraussen J, Stinissen P, et al. B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol. 2015 Dec 21;6:642. doi: 10.3389/fimmu.2015. 00642. eCollection 2015.</mixed-citation><mixed-citation xml:lang="en">Claes N, Fraussen J, Stinissen P, et al. B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol. 2015 Dec 21;6:642. doi: 10.3389/fimmu.2015. 00642. eCollection 2015.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Попова ЕВ, Брюхов ВВ, Бойко АН и др. Первично-прогрессирующий рассеянный склероз как атипичный демиелинизирующий процесс. Журнал неврологии и психиатрии им. С.С. Корсакова 2016;10(2):42-6.</mixed-citation><mixed-citation xml:lang="en">Popova EV, Bryukhov VV, Boiko AN, et al. Primary-progressive multiple sclerosis as an atypical demyelinating process. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 2016; 10(2):42-6. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hauser SL, Bar-Or A, Comi G; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.</mixed-citation><mixed-citation xml:lang="en">Hauser SL, Bar-Or A, Comi G; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Montalban X, Hauser SL, Kappos L; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.</mixed-citation><mixed-citation xml:lang="en">Montalban X, Hauser SL, Kappos L; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению окрелизумаба (OCREVUS®). Министерство здравоохранения Российской Федерации http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1e285065- d8dd-4438-b4f8-6358eced347c&amp;t=</mixed-citation><mixed-citation xml:lang="en">Instruction for medical use of ocrelizumab (OCREVUS). Ministry of health of the Russian Federation http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1e285065- d8dd-4438-b4f8-6358eced347c&amp;t=</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kappos L, Hauser SL, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. 69th Annual Meeting. April 22–28. Boston; 2017. AAN Poster #407.</mixed-citation><mixed-citation xml:lang="en">Kappos L, Hauser SL, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. 69th Annual Meeting. April 22–28. Boston; 2017. AAN Poster #407.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Давыдовская МВ, Хачанова НВ, Евдошенко ЕП и др. Рекомендации по алгоритму выбора препарата и плану управления рисками терапии натализумабом у пациентов с ремиттирующим рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова 2016;10(2):79-97.</mixed-citation><mixed-citation xml:lang="en">Davydovskaya MV, Khachanova NV, Evdoshenko EP, et al. Recommendations on drug selection algorithm and risk management plan for Natalizumab therapy in patients with remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;10(2):79-97. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017 Nov;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29.</mixed-citation><mixed-citation xml:lang="en">Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017 Nov;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Алифирова ВМ, Бисага ГН, Бойко АН и др. Клинические рекомендации по применению препарата алемтузумаб. Журнал неврологии и психиатрии им. С.С. Корсакова 2017;2(2):115-26.</mixed-citation><mixed-citation xml:lang="en">Alifirova VM, Bisaga GN, Boiko AN, et al. Clinical guidelines for the use of the drug alemtuzumab. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;2(2):115-26. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Трошина ЕА, Свириденко НЮ, Ванушко ВЭ и др. Федеральные клинические рекомендации по диагностике и лечению тиреотоксикоза с диффузным зобом (диффузный токсический зоб, болезнь Грейвса-Базедова), узловым/многоузловым зобом. Москва; 2014.</mixed-citation><mixed-citation xml:lang="en">Troshina EA, Sviridenko NYu, Vanushko VE, et al. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu tireotoksikoza s diffuznym zobom (diffuznyi toksicheskii zob, bolezn' Greivsa-Bazedova), uzlovym/mnogouzlovym zobom [Federal clinical guidelines for the diagnosis and treatment of thyrotoxicosis with diffuse goiter (diffuse toxic goiter, GravesBazedov disease), nodular / multi-nodular goiter]. Moscow; 2014.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rotondi M, Molteni M, Leporati P, et al. Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSHReceptor Immune Response. Front Endocrinol (Lausanne). 2017 Sep 28;8:254. doi: 10.3389/fendo.2017.00254. eCollection 2017.</mixed-citation><mixed-citation xml:lang="en">Rotondi M, Molteni M, Leporati P, et al. Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSHReceptor Immune Response. Front Endocrinol (Lausanne). 2017 Sep 28;8:254. doi: 10.3389/fendo.2017.00254. eCollection 2017.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Бойко АН, Бойко ОВ, Гусев ЕИ. Выбор оптимального препарата патогенетического лечения рассеянного склероза: современное состояние проблемы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;10(2): 77-91.</mixed-citation><mixed-citation xml:lang="en">Boiko AN, Boiko OV, Gusev EI. Selection of the optimal drug for pathogenetic treatment of multiple sclerosis: the current state of the problem. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;10(2):77-91. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wolinsky J, Giovannoni G, Hemmer B, et al. Ocrelizumab Efficacy in PPMS Patients in the Presence/Absence of T1 GadoliniumEnhancing Lesions at Baseline in a Phase III Placebo-Controlled Trial. The 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers. June 1-4. National Harbor; 2016. Oral Presentation DX06.</mixed-citation><mixed-citation xml:lang="en">Wolinsky J, Giovannoni G, Hemmer B, et al. Ocrelizumab Efficacy in PPMS Patients in the Presence/Absence of T1 GadoliniumEnhancing Lesions at Baseline in a Phase III Placebo-Controlled Trial. The 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers. June 1-4. National Harbor; 2016. Oral Presentation DX06.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Naismith RT, Cascione M, Grimaldi LME, et al. Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study. Academy of Managed Care Pharmacy (AMCP) 5th Nexus Conference. October 16-19. Dallas; 2017.</mixed-citation><mixed-citation xml:lang="en">Naismith RT, Cascione M, Grimaldi LME, et al. Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study. Academy of Managed Care Pharmacy (AMCP) 5th Nexus Conference. October 16-19. Dallas; 2017.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Алифирова ВМ, Бахтиярова КЗ, Белова АН и др. Клинические рекомендации по применению препарата терифлуномид. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;10(2):96-102.</mixed-citation><mixed-citation xml:lang="en">Alifirova VM, Bakhtiyarova KZ, Belova AN, et al. Clinical recommendations for the use of the drug teriflunomide. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;10(2):96-102. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Хачанова НВ, Давыдовская МВ, Евдошенко ЕП. Обновленная стратификация риска и план минимизации рисков развития натализумаб-ассоциированной прогрессирующей мультифокальной лейкоэнцефалопатии. Русский медицинский журнал. 2017; (13):3–7.</mixed-citation><mixed-citation xml:lang="en">Khachanova NV, Davydovskaya MV, Evdoshenko EP. Updated risk stratification and risk minimization plan for natalizumab-associated progressive multifocal leukoencephalopathy. Russkii meditsinskii zhurnal. 2017;(13):3–7. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Giovannoni G, Marta M, Davis A, et al. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Pract Neurol. 2016 Oct;16(5):389-93. doi: 10.1136/practneurol-2015-001355. Epub 2016 Apr 25.</mixed-citation><mixed-citation xml:lang="en">Giovannoni G, Marta M, Davis A, et al. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Pract Neurol. 2016 Oct;16(5):389-93. doi: 10.1136/practneurol-2015-001355. Epub 2016 Apr 25.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Willis M, Pearson O, Illes Z, et al. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017 Jan 10;4(2): e320. doi: 10.1212/NXI.0000000000000320. eCollection 2017 Mar.</mixed-citation><mixed-citation xml:lang="en">Willis M, Pearson O, Illes Z, et al. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017 Jan 10;4(2): e320. doi: 10.1212/NXI.0000000000000320. eCollection 2017 Mar.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lugaresi A, di Ioia M, Travaglini D, et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2013;9:893-914. doi: 10.2147/NDT.S45144. Epub 2013 Jun 24.</mixed-citation><mixed-citation xml:lang="en">Lugaresi A, di Ioia M, Travaglini D, et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2013;9:893-914. doi: 10.2147/NDT.S45144. Epub 2013 Jun 24.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011 Sep;68(9):1156-64. doi: 10.1001/archneurol.2011.103. Epub 2011 May 9.</mixed-citation><mixed-citation xml:lang="en">Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011 Sep;68(9):1156-64. doi: 10.1001/archneurol.2011.103. Epub 2011 May 9.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Захарова НА, Семиглазов ВФ, Манихас ГМ. Клинические рекомендации РООМ по скринингу РМЖ. Москва; 2014. http://breastcancersociety.ru/rek/view/201</mixed-citation><mixed-citation xml:lang="en">Zakharova NA, Semiglazov VF, Manikhas GM. Clinical guidelines of the Russian society of Oncomammology for breast cancer screening. Moscow; 2014. http://breastcancersociety.ru/rek/view/201</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
